What are biosimilars and how do they impact pharmaceutical companies?

Biosimilars are biological products highly similar to an already approved biological medicine. They are not exact generics but aim to provide similar efficacy and safety. For companies like Amgen Inc., biosimilar competition can erode sales of key blockbuster drugs, creating pressure on revenue and market share, necessitating strategic responses such as pipeline diversification and cost management.

What is meant by a "robust oncology portfolio" and why is it important for a biopharma company?

A "robust oncology portfolio" refers to a strong and diverse collection of cancer treatments. For a company like Amgen Inc., this signifies multiple successful drugs, such as Lumakras, addressing various cancer types. It is crucial for sustained revenue growth, establishing a strong market presence, and reducing reliance on any single product, thereby enhancing long-term stability.

How does the Price-to-Earnings (P/E) ratio help assess a company's valuation?

The P/E ratio is a valuation metric comparing a company's share price to its earnings per share. It indicates how much investors are willing to pay for each pound of a company's earnings. A lower P/E, such as Gilead Sciences Inc.'s 14.19, might suggest an attractive valuation, potentially indicating the stock is undervalued compared to its industry peers, assuming consistent earnings.

What are the implications of "biosimilar competition" for investors?

For investors, biosimilar competition typically implies a threat to the market exclusivity and revenue streams of established blockbuster drugs. Companies facing this, such as Amgen Inc. with products like Enbrel and Prolia, may experience reduced sales and profitability, potentially impacting dividend growth and overall financial performance. This often necessitates a focus on innovation and new product development.

How do "high R&D expenses" affect a company's financial health and future prospects?

High Research and Development (R&D) expenses, as seen with Amgen Inc.'s obesity drug progress, can initially weigh on a company's profit margins and earnings. However, these investments are vital for driving future growth by developing new drugs and expanding the product pipeline. Successful R&D can lead to lucrative new revenue streams, market leadership, and long-term shareholder value.

Why would an "attractive valuation" be considered a positive for a stock?

An attractive valuation, like Gilead Sciences Inc.'s forward P/E of 14.19 trading at a discount, suggests that the company's shares may be undervalued relative to its earnings potential or compared to competitors. This could appeal to investors looking for growth opportunities at a reasonable price, as the stock might have significant room for appreciation if its performance improves or market sentiment shifts.

What might "insider sales" indicate to potential investors?

Insider sales refer to company executives or directors selling their own shares. While there can be various personal reasons for such transactions, significant or widespread insider selling, as observed with Gilead Sciences Inc., might signal that those closest to the company perceive limited near-term upside or have concerns about its future performance. Investors often monitor these actions closely.

How do "regulatory delays" affect a biotechnology company's market position?

Regulatory delays, such as those impacting Amgen Inc.'s novel assets like MariTide, can significantly affect a biotechnology company's market position. They delay the launch of potentially lucrative products, postponing revenue generation and allowing competitors to advance. Such delays increase uncertainty, can erode investor confidence, and impact market share, making pipeline execution a critical factor for success.

What is the significance of a "dominant franchise" within a specific disease area like HIV?

A dominant franchise, such as Gilead Sciences Inc.'s strong position in the HIV market with products like Yeztugo and Descovy, provides a stable and predictable revenue stream. This leadership establishes the company as a key player in that therapeutic area, offering a competitive advantage, supporting further investment in related research, and enhancing overall market stability and recognition.

How should a beginner interpret the information provided on this comparison page?

Beginners should interpret this page as an educational tool to understand various financial and market aspects of companies like Amgen Inc. and Gilead Sciences Inc. It offers general insights and context for comparing two biotechnology firms. Please remember, this content is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Always conduct your own comprehensive research before making investment decisions.

Live Report · Updated 24 August 2026

Amgen vs Gilead Sciences

Large biotech company with established medicines and steady dividends vs Pharmaceutical giant with HIV hepatitis and cancer treatments. Which is the better buy for your portfolio in August 2026? Plain-English answer below.

Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates HIV and liver disease treatments and has spent years trying to diversify into oncology. Both large-cap biotechs generate prodigious free cash flow and return capital aggressively, yet their pipeline profiles and therapeutic concentrations differ significantly. The Amgen vs Gilead Sciences breakdown shows investors how patent cliff exposure, pipeline depth, and capital allocation choices separate two cash-rich biotech giants navigating the next decade of drug approvals.

Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates...

Comparison Snapshot

Key Financial Metrics

AMGN

Metric

GILD

$239.09B

Market Cap

$184.47B

-21.07%

Potential Profit

-6.87%

Hold

Analyst Rating

Buy

Why It’s Moving

Amgen’s strong earnings haven’t erased analyst caution as valuation pressure keeps downside risk in focus.

Amgen’s latest quarterly report showed revenue up 10% to $10.1 billion and adjusted EPS above expectations, but the market is now focused on whether that momentum can keep up after the post-earnings run.
Analysts are still signaling downside because the stock has moved close to its highs, making valuation look stretched even after strong results.
Recent chatter around insider share sales and a still-mixed analyst stance has added to the caution, suggesting some investors are locking in gains rather than chasing the move.

Sentiment:

🐻Bearish

Gilead’s rally is running into analyst skepticism as investors weigh strong core growth against a limited margin for error.

Shares have been pressured by analyst caution even after Gilead’s latest quarter showed stronger-than-expected earnings and revenue growth, as investors focus on whether recent gains can keep offsetting slower products.
The company’s HIV and oncology franchises remain the main growth engine, but ongoing weakness in Veklury underscores how dependent the story is on a few core therapies.
Recent coverage has also highlighted that the stock already reflects a sizable amount of good news, leaving little room for error if execution or guidance cools from here.

Sentiment:

🐻Bearish

Amgen’s strong earnings haven’t erased analyst caution as valuation pressure keeps downside risk in focus.

Amgen’s latest quarterly report showed revenue up 10% to $10.1 billion and adjusted EPS above expectations, but the market is now focused on whether that momentum can keep up after the post-earnings run.
Analysts are still signaling downside because the stock has moved close to its highs, making valuation look stretched even after strong results.
Recent chatter around insider share sales and a still-mixed analyst stance has added to the caution, suggesting some investors are locking in gains rather than chasing the move.

Sentiment:

🐻Bearish

Gilead’s rally is running into analyst skepticism as investors weigh strong core growth against a limited margin for error.

Shares have been pressured by analyst caution even after Gilead’s latest quarter showed stronger-than-expected earnings and revenue growth, as investors focus on whether recent gains can keep offsetting slower products.
The company’s HIV and oncology franchises remain the main growth engine, but ongoing weakness in Veklury underscores how dependent the story is on a few core therapies.
Recent coverage has also highlighted that the stock already reflects a sizable amount of good news, leaving little room for error if execution or guidance cools from here.

Sentiment:

🐻Bearish

Investment Analysis

Amgen

AMGN

Pros

Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.

Considerations

Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
High R&D expenses pressure margins despite obesity drug progress in early stages.
Regulatory delays in novel assets like MariTide expose pipeline execution risks.

Gilead Sciences

GILD

Pros

Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
Expanding oncology pipeline nears key regulatory milestones for sustained growth.

Considerations

Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
Recent insider sales signal potential short-term concerns over performance.
Modest consensus price target implies limited near-term upside from current levels.

Related Market Insights

Cancer Therapies: What's Next After 100% Response Rate

Regeneron's 100% response rate signals a new era in cancer treatment. Explore investment opportunities in immuno-oncology & breakthrough therapies with Nemo.